Establishing a framework for full-scale clinical development following RUO launch
First written in FY2016-Q4. 20 of 23 entries say "Restated". Latest entry: FY2023-Q1.
1 other company's latest entry also says "Restated".
- FY2023-Q1RestatedAnnual report
「In research and development, we continued to promote R&D aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”) and developing new services in the healthcare solutions business.」
Continuing research and development aimed at commercializing depression biomarkers and developing new services. - FY2022-Q3RestatedAnnual report
「In this business segment, we efficiently continued joint research and joint development of PEA (a depression biomarker) in the mental health field and the expansion of contract research testing services, among other initiatives. We also continued to promote research and development for the rollout of the biomarker discovery service and support for healthcare solutions development.」
Continuing joint research and joint development of PEA, expansion of contract research testing services, rollout of the discovery service, and research and development to support development. - FY2022-Q1RestatedAnnual report
「In this business segment, we efficiently continued the joint development of PEA (a depression biomarker) and the expansion of contract research testing services, among other initiatives. We also continued to work on development toward the launch of a biomarker discovery service and the promotion of joint development for healthcare solutions services.」
Continuing the joint development of PEA, expansion of contract research testing services, and development toward the launch of a biomarker discovery service, among other initiatives. - FY2021RestatedAnnual report
「In this business segment, we efficiently continued joint research on PEA (a depression biomarker), measurement method development, and joint research on biomarkers for mild cognitive impairment, among other initiatives.」
Continuing joint research on PEA and measurement method development, as well as joint research on biomarkers for mild cognitive impairment. - FY2021-Q3RestatedAnnual report
「In this business segment, we efficiently continued the joint development of PEA (a depression biomarker), measurement method development, and the expansion of contract research testing services, among other initiatives.」
Continuing the joint development of PEA, measurement method development, and the expansion of contract research testing services. - FY2021-Q2RestatedAnnual report
「In this business segment, we continued the joint development of PEA (a depression biomarker), measurement method development, and the expansion of contract research testing services, among other initiatives.」
Continuing the joint development of PEA, measurement method development, and the expansion of contract research testing services. - FY2021-Q1RestatedAnnual report
「In this business segment, we continued to expand contract research testing services for PEA (a depression biomarker) and develop measurement methods, among other initiatives.」
Continuing to expand contract research testing services for PEA and develop measurement methods. - FY2020RestatedAnnual report
「In this business segment, toward the practical application and commercialization of depression biomarkers, we continued to develop measurement methods and undertake activities toward clinical research, including clinical performance evaluation.」
Continuing measurement method development and activities toward clinical research, including clinical performance evaluation. - FY2020-Q3RestatedAnnual report
「In this business segment, toward the practical application and commercialization of depression biomarkers, we continued to develop measurement methods and undertake activities toward clinical research, including clinical performance evaluation.」
Continuing to develop measurement methods and undertake activities toward clinical research, including clinical performance evaluation. - FY2020-Q2RestatedAnnual report
「In this business segment, toward the practical application and commercialization of depression biomarkers, we continued to develop measurement methods and undertake activities toward clinical research, including clinical performance evaluation.」
Continuing measurement method development and activities toward clinical research, including clinical performance evaluation. - FY2020-Q1RestatedAnnual report
「In this business segment, toward the practical application and commercialization of depression biomarkers, we continued to develop measurement methods and undertake activities toward clinical research, including clinical performance evaluation.」
Continuing measurement method development and activities toward clinical research, including clinical performance evaluation. - FY2019RestatedAnnual report
「We will continue to focus on establishing the framework for confirming the clinical utility of PEA and rebuilding a new portfolio.」
Continuing clinical research activities, including clinical performance evaluation, and organizational preparations for commercialization. - FY2019-Q3RestatedAnnual report
「In this business segment, toward the practical application and commercialization of depression biomarkers, we continued to develop measurement methods and undertake activities toward clinical research, including clinical performance evaluation.」
Continuing measurement method development and activities toward clinical research, including clinical performance evaluation. - FY2019-Q2RestatedAnnual report
「In this business segment, toward the practical application and commercialization of depression biomarkers, we continued to develop measurement methods and undertake activities toward clinical research, including clinical performance evaluation, while also considering new pipelines and biomarker-related businesses.」
Continuing measurement method development and activities toward clinical research, including clinical performance evaluation. - FY2019-Q1RestatedAnnual report
「In this business segment, toward the practical application and commercialization of depression biomarkers, we worked to develop measurement methods using instrumental and enzymatic methods, among others, and undertook activities and organizational preparations for clinical research.」
Continuing measurement method development, activities toward clinical research, and organizational preparations. - FY2018-Q4AdvancedAnnual report
「Toward the practical application and commercialization of depression biomarkers, we worked to develop measurement methods using instrumental and enzymatic methods, among others, and to establish a quality management system for clinical research.」
Toward clinical research, continuing to develop measurement methods and establish a quality management system as specific organizational preparations. - FY2018-Q2AdvancedAnnual report
「We also began a feasibility study and undertook other initiatives, including preparations for establishing a study group, toward clinical trials using depression biomarkers.」
Specific steps toward full-scale clinical research are described, including the launch of a feasibility study and preparations for establishing a study group. - FY2018-Q1RestatedAnnual report
「We also worked to establish the necessary framework with partner medical institutions and undertake other initiatives toward clinical research using depression biomarkers.」
Continuing to establish the necessary framework with partner medical institutions for clinical research using depression biomarkers. - FY2017-Q4RestatedAnnual report
「We also worked to establish the necessary framework with partner medical institutions and undertake other initiatives toward clinical research using depression biomarkers.」
Continuing to establish the necessary framework with partner medical institutions for clinical research using depression biomarkers. - FY2017RestatedAnnual report
「We also continued to focus on paid contract clinical testing for major depressive disorder through partnerships with psychiatric hospitals.」
Continuing paid contract clinical testing and initiatives toward clinical development through partnerships with medical institutions. - FY2017-Q2RestatedAnnual report
「In addition, using the combined capabilities of M3,Inc. and its group companies, our capital and business alliance partner, we undertook promotional activities and other initiatives aimed at disseminating depression biomarkers, as well as identifying partner medical institutions and undertaking other initiatives toward full-scale clinical development.」
Continuing to identify partner medical institutions for full-scale clinical development. - FY2017-Q1RestatedAnnual report
「In addition, we worked to identify partner medical institutions and undertake other initiatives in preparation for full-scale clinical development following the RUO launch.」
Continuing to identify partner medical institutions in preparation for clinical development following the RUO launch. - FY2016-Q4First statedAnnual report
「We worked to identify partner medical institutions and undertake other initiatives in preparation for full-scale clinical development following the RUO launch.」
The identification of partner medical institutions is described as preparation for clinical development following the RUO launch.